If you take semaglutide and you are thinking about having a baby, or you have just found out you are pregnant, the question arrives with a mix of urgency and worry. The short answer, according to the FDA label, is both clear and reassuring when it is planned for: GLP-1 medications like semaglutide are not recommended during pregnancy, and the label advises discontinuing semaglutide at least 2 months before a planned pregnancy because of its long half-life. Wegovy: prescribing information
That does not mean something is wrong or that you should be alarmed. It means timing matters, and that with a little planning this is an orderly conversation with your care team, not an emergency. Here is why the recommendation exists, what the science says about how long the medication stays in the body, and what to do in each situation. All of it is grounded in FDA prescribing information. None of it replaces guidance from your clinician. Wegovy: prescribing information
The instructions differ: semaglutide has a recommendation to stop at least two months before a planned pregnancy; tirzepatide has a specific four-week oral-contraception precaution after starting and after each increase. Zepbound: prescribing information
The FDA label is direct: when a pregnancy is recognized, semaglutide should be discontinued. There are two reasons behind that instruction, and it helps to understand both without overstating them. Wegovy: prescribing information
The first is a lack of adequate human data. The label itself notes that the available pharmacovigilance data and data from clinical trials in pregnant patients are insufficient to establish, or to rule out, a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In other words, it has not been studied enough in pregnancy to be considered safe, and in medicine the absence of proof of safety is handled with caution.
The second reason comes from the animal studies. In rats, rabbits, and monkeys, giving semaglutide during organogenesis was associated with early pregnancy losses, structural abnormalities, and alterations in growth, in some cases at exposures below the maximum recommended human dose. The label sums it up this way: based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy.
There is a third point the FDA raises that helps explain the reasoning: weight loss offers no benefit to a pregnant patient and may cause fetal harm. Pregnancy is a time when appropriate weight gain based on pre-pregnancy weight is recommended, which is the opposite of semaglutide’s main effect.
To understand the recommendation to stop two months ahead, it helps to look at how the molecule behaves in the body.
Semaglutide is a GLP-1 receptor agonist: it mimics a natural gut hormone that regulates appetite and fullness. But what matters here is how long it lasts. According to the prescribing information, semaglutide has an elimination half-life of approximately one week, and by design it stays in the circulation for roughly 5 to 7 weeks after the last dose.
This is semaglutide, a GLP-1 receptor agonist. Its long half-life of about one week means it stays in the body for several weeks, which is why the label advises stopping it well in advance (about 2 months) before trying to conceive.
That is the reason for the two-month window. It is not an arbitrary number: it is meant to give the medication enough time to clear before conception, rather than have it still present during the earliest and most sensitive weeks of development. You can see the full picture of this hormonal pathway in our guide to how GLP-1 medications work.
This is where planning changes everything. If you have it in mind to try for a pregnancy, the most important step is to talk it through with your clinician ahead of time, before stopping anything on your own.
That conversation usually covers three things: when to stop semaglutide to respect the roughly two-month window, how to support weight management during the planning period without the medication, and what to expect in terms of appetite and habits once the effect fades. It is not a decision you make alone or overnight; it is a plan built together and matched to your situation. This is exactly the kind of moment where physician-led care and steady care coaching help most, so the timing fits your life rather than catching you off guard.
Many people also ask about contraception during this stage, and for good reason: the plan to stop the medication and the plan to try for a pregnancy go hand in hand. If it is not the right time yet, keeping a reliable contraceptive method while taking semaglutide is part of the conversation; and when the time does come, stopping is coordinated around the window the label advises. The underlying idea is simple: line up the moment of conception with the moment the medication has already cleared the body, and that comes from planning rather than improvising.
If you are weighing treatment options with your clinician before or after this stage, our guide to semaglutide vs tirzepatide explains how the two molecules differ. The decision about which to use, and when, always belongs to a licensed clinician.
This is the scenario that causes the most anxiety, so it is worth saying calmly and precisely: if semaglutide is being used for weight management, stop treatment when pregnancy is recognized and contact your clinician promptly for follow-up.
The action the FDA label describes is to discontinue semaglutide when the pregnancy is recognized, and to advise the patient of the risk to the fetus. But the how and the next steps are coordinated by your care team, who knows your full history. An unplanned pregnancy during treatment is not a reason to panic; it is a reason for a quick call to your clinician. Novo Nordisk also maintains a pregnancy exposure registry to follow these cases, something your clinician can walk you through. Wegovy: prescribing information
If you want to understand what it feels like to come off the medication and which effects are normal, our guide to GLP-1 side effects can help you know what to expect.
This is one of the most common worries, and it deserves a careful answer. The FDA label is clear on a point that anxiety often drowns out: the available data are insufficient to establish a drug-associated risk of major birth defects or miscarriage. In other words, there is no confirmation that an early exposure causes harm; what exists is not enough information to rule it out, which is why the approach is one of caution. Wegovy: prescribing information
It also helps to have context on the baseline numbers. The label itself notes that in the U.S. general population, the background risk of major birth defects in recognized pregnancies is about 2 to 4 percent, and the risk of miscarriage is about 15 to 20 percent. Those numbers exist in every pregnancy, with or without medication. Pointing to them is not meant to minimize the situation, but to keep fear from filling the gaps with conclusions the evidence does not support.
The right response, then, is not panic or guilt: it is a call to your clinician to review your case, stop the medication, and follow up with your care team. Having taken one or several doses before you knew is a known and manageable situation, not an emergency to solve alone online.
The recommendation depends on the formulation. Wegovy tablets: breastfeeding is not recommended during treatment. A lactation study of oral semaglutide found semaglutide below the quantification limit, but detected SNAC or its metabolites in human milk. Possible accumulation in the infant explains the recommendation.
Wegovy injection: section 8.2 of the label describes no data on the presence of subcutaneously administered semaglutide in human milk, effects on the infant or milk production. It calls for weighing breastfeeding benefits against maternal clinical need and potential risks. This is not a safety guarantee. Compounded semaglutide also requires review of the exact formulation and clinical situation. Wegovy: section 8.2, lactation
GLP-1 medications like semaglutide are not recommended during pregnancy. The FDA label advises discontinuing semaglutide at least two months before a planned pregnancy because of its long half-life, and stopping it once a pregnancy is recognized. Human data are limited and animal studies showed potential fetal harm, so caution is the correct approach. And above all: do not stop or change a prescribed medication on your own. Talk to your clinician about the timing and the plan that fit your situation. Wegovy: prescribing information
GLP-1 medications are FDA-approved for specific indications. Eligibility is determined by a clinician. This is general education and does not replace your clinician’s advice.
At REMEVi you can talk with a physician-led care team that helps you plan safely, with your history and your timing at the center of the decision, plus transparent pricing and coaching along the way. Real medical care, no rush. Visit remevihealth.com to get started.
Your Health. Your Terms.
It is not recommended. FDA prescribing information says to discontinue semaglutide when a pregnancy is recognized, because the available data are not enough to rule out risk to the fetus and animal studies showed potential harm. This is not medical advice: if you are pregnant or think you might be, talk to your clinician before changing anything.
The FDA label advises discontinuing semaglutide at least 2 months before a planned pregnancy because of its long half-life of about one week. The medication stays in the circulation for several weeks after the last dose, and that window is meant to clear it before conception. Your clinician sets the exact plan.
If using semaglutide for weight management, stop it when pregnancy is recognized and contact your prescriber promptly to review the exposure and next steps.
Tirzepatide acts on the same GLP-1 pathway and shares class-level safety considerations in pregnancy; its label also advises caution and planning. Which medication fits your situation, and how to handle the timing, is an individual clinical decision made with your clinician.
It depends on the formulation. Wegovy labeling advises against breastfeeding during tablet treatment because of infant exposure to SNAC or its metabolites. For injection, the label describes a lack of data and calls for weighing breastfeeding benefits, maternal need and risks. A compounded preparation needs its own assessment; it does not inherit another formulation’s safety.
Free 1-minute quiz, then a 2-minute intake if you qualify. A licensed clinician reviews your information. If prescribed, medication is delivered to your door.
See if you qualifyFree · about 1 minute · no card required
